Local pretreatment with the cannabinoid CB1 receptor antagonist AM251 attenuates methamphetamine intra-accumbens self-administration

Neuroscience Letters

Volumn 489, Issue 3, 2011, Pages 187-191

  Rodriguez, Jesse S ^a   Boctor, Sherin Y ^a   Flores, Luke C ^a   Phelix, Clyde F ^a   Martinez, Joe L ^a  

^a UNIVERSITY OF TEXAS AT SAN ANTONIO   (United States)

Author keywords

Drug taking; Endocannabinoid; Intracranial self administration; Psychostimulant; Reverse microdialysis

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; METHAMPHETAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; MALE; NEGATIVE FEEDBACK; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; RAT; SPRAGUE DAWLEY RAT; SUBSTANCE ABUSE; VENTRAL TEGMENTUM;

ANIMALS; CENTRAL NERVOUS SYSTEM STIMULANTS; CONDITIONING, OPERANT; DRUG INTERACTIONS; MALE; METHAMPHETAMINE; MICRODIALYSIS; NUCLEUS ACCUMBENS; PIPERIDINES; PYRAZOLES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, CANNABINOID, CB1; SELF ADMINISTRATION;

EID: 78751566490     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2010.12.013     Document Type: Article

References (47)

1. Bergman J., Delatte M.S., Paronis C.A., Vemuri K., Thakur G.A., Makriyannis A. Some effects of CB1 antagonists with inverse agonist and neutral biochemical properties. Physiol. Behav. 2008, 93(4-5):666-670.
2. Berke J.D., Hyman S.E. Addiction, dopamine, and the molecular mechanisms of memory. Neuron 2000, 25:515-532.
3. Boctor S.Y., Martinez J.L., Koek W., France C.P. The cannabinoid CB1 receptor antagonist AM251 does not modify methamphetamine reinstatement of responding. Eur. J. Pharmacol. 2007, 571:39-43.
4. Centonze D., Battista N., Rossi S., Mercuri N.B., Finazzi-Agro A., Bernardi G., Calabresi P., Maccarrone M. A critical interaction between dopamine D2 receptors and endocannabinoids mediates the effects of cocaine on striatal GABAergic transmission. Neuropsychopharmacology 2004, 29:1488-1497.
5. Chevrette J., Stellar J.R., Hesse G.W., Markou A. Both the shell of the nucleus accumbens and the central nucleus of the amygdala support amphetamine self-administration in rats. Pharmacol. Biochem. Behav. 2002, 71:501-507.
6. Chiang Y.C., Chen J.C. The role of the cannabinoid type 1 receptor and down-stream cAMP/DARPP-32 signal in the nucleus accumbens of methamphetamine-sensitized rats. J. Neurochem. 2007, 103:2505-2517.
7. Corbillé A.G., Valjent E., Marsicano G., Ledent C., Lutz B., Hervé D., Girault J.A. Role of cannabinoid type 1 receptors in locomotor activity and striatal signaling in response to psychostimulants. J. Neurosci. 2007, 27:6937-6947.
8. Darmani N.A. Delta-9-tetrahydrocannabinol and synthetic cannabinoids prevent emesis produced by the cannabinoid CB1 receptor antagonist/inverse agonist SR141716A. Neuropsychopharmacology 2001, 24:198-203.
9. De Vries T.J., Schoffelmeer A.N. Cannabinoid CB1 receptors control conditioned drug seeking. Trends Pharmacol. Sci. 2005, 26:420-426.
10. Fowler J.S., Kroll C., Ferrieri R., Alexoff D., Logan J., Dewey S.L., Schiffer W., Schlyer D., Carter P., King P., Shea C., Xu Y., Muench L., Benveniste H., Vaska P., Volkow N.D. PET studies of d-methamphetamine pharmacokinetics in primates: comparison with l-methamphetamine and (--)-cocaine. J. Nucl. Med. 2007, 48::1724-1732.
11. Freund T.F., Katona I., Piomelli D. Role of endogenous cannabinoids in synaptic signaling. Physiol. Rev. 2003, 83:1017-1066.
12. Gerdeman G.L., Lovinger D.M. Emerging roles for endocannabinoids in long-term synaptic plasticity. Br. J. Pharmacol. 2003, 140:781-789.
13. Giuffrida A., Parsons L.H., Kerr T.M., Rodriguez de Fonseca F., Navarro M., Piomelli D. Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nat. Neurosci. 1999, 2:358-363.
14. Heimer L., Zahm D.S., Churchill L., Kalivas P.W., Wohltmann C. Specificity in the projection patterns of accumbal core and shell in the rat. Neuroscience 1991, 41:89-125.
15. Hoebel B.G., Monaco A.P., Hernandez L., Aulisi E., Stanley B.G., Lenard L. Self-injection of amphetamine directly into the brain. Psychopharmacology (Berl) 1983, 81:158-163.
16. Kahlig K.M., Binda F., Khoshbouei H., Blakely R.D., McMahon D.G., Javitch J.A., Galli A. Amphetamine induces dopamine efflux through a dopamine transporter channel. Proc. Natl. Acad. Sci. 2005, 102:3495-3500.
17. Kokoshka J.M., Vaughan R.A., Hanson G.R., Fleckenstein A.E. Nature of methamphetamine-induced rapid and reversible changes in dopamine transporters. Eur. J. Pharmacol. 1998, 361:269-275.
18. Koob G.F., Swerdlow N.R. The functional output of the mesolimbic dopamine system. Ann. N.Y. Acad. Sci. 1988, 537::216-227.
19. Landa L., Sulcova A., Slais K. Involvement of cannabinoid CB1 and CB2 receptor activity in the development of behavioural sensitization to methamphetamine effects in mice. Neuro. Endocrinol. Lett. 2006, 27:63-69.
20. Maldonado R., Valverde O., Berrendero F. Involvement of the endocannabinoid system in drug addiction. Trends Neurosci. 2006, 29:225-232.
21. McLaughlin P.J., Winston K.M., Limebeer C.L., Parker L.A., Makriyannis A., Salamone J.D. The cannabinoid antagonist AM 2511 produces food avoidance and behavioras associated with nausea but does not impair feeding efficiency in rats. Psychopharmacology 2005, 180(2):286-293.
22. Onaivi E.S. An endocannabinoid hypothesis of drug reward and drug addiction. Ann. N.Y. Acad. Sci. 2008, 1139:412-421.
23. Parolaro D., Rubino T. The role of the endogenous cannabinoid system in drug addiction. Drug News Perspect. 2008, 21:149-157.
24. Patel S., Rademacher D.J., Hillard C.J. Differential regulation of the endocannabinoids anandamide and 2-arachidonylglycerol within the limbic forebrain by dopamine receptor activity. J. Pharmacol. Exp. Ther. 2003, 306:880-888.
25. Paxinos G., Watson C. The Rat Brain In Reply to Stereotaxic Coordinates 1998, Academic Press, New York. 4th ed.
26. Pertwee R.G. Inverse agonism and neutral antagonism at cannabinoid CB1 receptors. Life Sci. 2005, 76(12):1307-1324.
27. Phillips G.D., Robbins T.W., Everitt B.J. Bilateral intra-accumbens self-administration of d-amphetamine: antagonism with intra-accumbens SCH-23390 and sulpiride. Psychopharmacology (Berl) 1994, 114:477-485.
28. Piomelli D. The molecular logic of endocannabinoid signalling. Nat. Rev. Neurosci. 2003, 4:873-884.
29. Price D.A., Owens W.A., Gould G.G., Frazer A., Roberts J.L., Daws L.C., Giuffrida A. CB1-independent inhibition of dopamine transporter activity by cannabinoids in mouse dorsal striatum. J. Neurochem. 2007, 101(2):389-396.
30. Price T.J., Patwardhan A., Akopian A.N., Hargreaves K.M., Flores C.M. Modulation of trigeminal sensory neuron activity by the dual cannabinoid-vanilloid agonists anandamide N-arachidonoyl-dopamine and arachidonyl-2-chloroethylamide. Br. J. Pharmacol. 2004, 141(7):1118-1130.
31. Rahman S., McBride W.J. Involvement of GABA and cholinergic receptors in the nucleus accumbens on feedback control of somatodendritic dopamine release in the ventral tegmental area. J. Neurochem. 2002, 80:646-654.
32. Results from the 2004 National Survey on Drug Abuse: National Findings (Office of Applied Studies, NSDUH Series H-28, DHHS Publication No. SMA 05-4062), Rockville, MD.
33. Ricoy U., Martinez J.L. Local hippocampal methamphetamine-induced reinforcement. Front Behav. Neurosci. 2009, 3:47.
34. Rodriguez J.S., Boctor S.Y., Phelix C.P., Martinez J.L. F344 rats self-administer methamphetamine but not amphetamine into the nucleus accumbens via revese microdialysis. Abstr.: Soc. Neurosci. Prog. 2003, 135:6.
35. Rodriguez J.S., Phelix C.P., Martinez J.L. Local oxytocin antagonist pretreament decreases intra-accumbens methamphetamine self-administration. Abstr.: Soc. Neurosci. Prog. 2005, 681:10.
36. Rodriguez J.S., Boctor S.Y., Phelix C.F., Martinez J.L. Differences in performance between Sprague-Dawley and Fischer 344 rats in positive reinforcement tasks. Pharmacol. Biochem. Behav. 2008, 89:17-22.
37. Schindler C.W., Panlilio L.V., Gilman J.P., Justinova Z., Vemuri V.K., Makriyannis A., Goldberg S.R. Effects of cannabinoid receptor antagonists on maintenance and reinstatement of methamphetamine self-administration in rhesus monkeys. Eur. J. Pharmacol. 2010, 633(1-3):44-49.
38. Seiden L.S., Sabol K.E., Ricaurte G.A. Amphetamine: effects on catecholamine systems and behavior. Annu. Rev. Pharmacol. Toxicol. 1993, 33:639-677.
39. Sharkey K.A., Cristino L., Oland L.D., Van Sickle M.D., Starowicz K., Pittman Q.J., Guglielmotti V., Davison J.S., Di Marzo V. Arvanil, anandamide and N-arachidonoyl-dopamine (NADA) inhibit emesis through cannabinoid CB1 and vanilloid TRPV1 receptors in the ferret. Eur. J. Neurosci. 2007, 25(9):2773-2782.
40. Sim-Selley L.J. Regulation of cannabinoid CB1 receptors in the central nervous system by chronic cannabinoids. Crit. Rev. Neurobiol. 2003, 15(2):91-119.
41. Stelten B.M., Noblesse L.H., Ackermans L., Temel Y., Visser-Vandewalle V The neurosurgical treatment of addiction. Neurosurg. Focus 2008, 25(1):E5.
42. Svingos A.L., Clarke C.L., Pickel V.M. Localization of the delta-opioid receptor and dopamine transporter in the nucleus accumbens shell: implications for opiate and psychostimulant cross-sensitization. Synapse 1999, 34(1):1-10.
43. Thiemann G., Di Marzo V., Molleman A., Hasenohrl R.U. The CB (1) cannabinoid receptor antagonist AM251 attenuates amphetamine-induced behavioural sensitization while causing monoamine changes in nucleus accumbens and hippocampus. Pharmacol. Biochem. Behav. 2008, 89:384-391.
44. Van Sickle M.D., Oland L.D., Ho W., Hillard C.J., Mackie K., Davison J.S., Sharkey K.A. Cannabinoids inhibit emesis through CB1 receptors in the brainstem of the ferret. Gastroenterology 2001, 121(4):767-774.
45. Vinklerova J., Novakova J., Sulcova A. Inhibition of methamphetamine self-administration rats by cannabinoid receptor antagonist AM251. Psychopharmacol 2002, 16:139-143.
46. Volkow N.D., Wang G.J., Fischman M.W., Foltin R., Fowler J.S., Franceschi D., Franceschi M., Logan J., Gatley S.J., Wong C., Ding Y.S., Hitzemann R., Pappas N. Effects of route of administration on cocaine induced dopamine transporter blockade in the human brain. Life Sci. 2000, 67(12):1507-1515.
47. Xi Z.X., Gilbert J.G., Peng X.Q., Pak A.C., Li X., Gardner E.L. Cannabinoid CB1 receptor antagonist AM251 inhibits cocaine-primed relapse in rats: role of glutamate in the nucleus accumbens. J. Neurosci. 2006, 26:8531-8536.